Biological
Afluria
Afluria is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_3
1
33%
Ph not_applicable
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
completed267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_4
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399
completednot_applicable
Immune Responses Induced by Different Licensed Influenza Vaccines
NCT00902278
completedphase_3
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
NCT01825200
Clinical Trials (3)
Showing 3 of 3 trials
NCT05170399Phase 4
Vaccine Responses in Patients With B Cell Malignancies
NCT00902278Not Applicable
Immune Responses Induced by Different Licensed Influenza Vaccines
NCT01825200Phase 3
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3